share_log
Moomoo 24/7 ·  Apr 19 07:13
Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 Armada Clinical Trial of Ocu410—a Modifier Gene Therapy
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment